Literature DB >> 23605177

Penicillamine revisited: historic overview and review of the clinical uses and cutaneous adverse effects.

Rim Ishak1, Ossama Abbas.   

Abstract

Penicillamine is a well-known heavy metal chelator, classically used in the treatment of Wilson disease, rheumatoid arthritis, and cystinuria. From a dermatologic standpoint, penicillamine was found to be useful in the treatment of systemic sclerosis. The successful therapeutic uses of penicillamine have been hindered by its numerous adverse effects, both cutaneous and extra-cutaneous. It is a unique drug since it provokes a diversity of dermatologic manifestations that include (1) acute hypersensitivity reactions, (2) dermopathies characterized by elastic fiber abnormalities including elastosis perforans serpiginosa and pseudo-pseudoxanthoma elasticum, (3) autoimmune disorders such as pemphigus and penicillamine-induced lupus erythematosus-like syndrome, and (4) miscellaneous dermatoses that result from undefined mechanisms. These cutaneous adverse effects may correlate with the dosage and duration of penicillamine therapy as well as the disease being treated.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23605177     DOI: 10.1007/s40257-013-0022-z

Source DB:  PubMed          Journal:  Am J Clin Dermatol        ISSN: 1175-0561            Impact factor:   7.403


  9 in total

1.  D-penicillamine-induced granulomatous hepatitis in brown Norway rats.

Authors:  Imir G Metushi; Xu Zhu; Jack Uetrecht
Journal:  Mol Cell Biochem       Date:  2014-04-27       Impact factor: 3.396

Review 2.  Co-occurring Wilson's disease and non-penicillamine-induced systematic lupus erythematosus: a case report and literature review.

Authors:  Wen Shi; Xiaoming Huang; Shengyu Zhang; Yang Jiao
Journal:  Clin Rheumatol       Date:  2020-10-15       Impact factor: 2.980

3.  Protective Effects of D-Penicillamine on Catecholamine-Induced Myocardial Injury.

Authors:  Michal Říha; Pavlína Hašková; Jan Martin; Tomáš Filipský; Kateřina Váňová; Jaroslava Vávrová; Magdalena Holečková; Pavel Homola; Libor Vítek; Vladimír Palicka; Tomáš Šimůnek; Přemysl Mladěnka
Journal:  Oxid Med Cell Longev       Date:  2015-12-14       Impact factor: 6.543

4.  Elastosis perforans serpiginosa: a review of the literature and our own experience.

Authors:  Adriana Polańska; Monika Bowszyc-Dmochowska; Ryszard W Żaba; Zygmunt Adamski; Adam Reich; Aleksandra Dańczak-Pazdrowska
Journal:  Postepy Dermatol Alergol       Date:  2016-10-21       Impact factor: 1.837

5.  α-Lipoic acid treatment prevents cystine urolithiasis in a mouse model of cystinuria.

Authors:  Tiffany Zee; Neelanjan Bose; Jarcy Zee; Jennifer N Beck; See Yang; Jaspreet Parihar; Min Yang; Sruthi Damodar; David Hall; Monique N O'Leary; Arvind Ramanathan; Roy R Gerona; David W Killilea; Thomas Chi; Jay Tischfield; Amrik Sahota; Arnold Kahn; Marshall L Stoller; Pankaj Kapahi
Journal:  Nat Med       Date:  2017-02-06       Impact factor: 53.440

6.  D-penicillamine-induced pseudo-pseudoxanthoma elasticum and extensive elastosis perforans serpiginosa with excellent response to acitretin.

Authors:  Muzamil Amin Chisti; Yousef Binamer; Abdullah Alfadley; Abdulmonem Almutawa
Journal:  Ann Saudi Med       Date:  2019 Jan-Feb       Impact factor: 1.526

Review 7.  Chelation therapy in liver diseases of childhood: Current status and response.

Authors:  Jayendra Seetharaman; Moinak Sen Sarma
Journal:  World J Hepatol       Date:  2021-11-27

8.  Comprehensive proteomic quantification of bladder stone progression in a cystinuric mouse model using data-independent acquisitions.

Authors:  Jacob Rose; Nathan Basisty; Tiffany Zee; Cameron Wehrfritz; Neelanjan Bose; Pierre-Yves Desprez; Pankaj Kapahi; Marshall Stoller; Birgit Schilling
Journal:  PLoS One       Date:  2022-06-30       Impact factor: 3.752

Review 9.  D-Penicillamine: The State of the Art in Humans and in Dogs from a Pharmacological and Regulatory Perspective.

Authors:  Michela Pugliese; Vito Biondi; Enrico Gugliandolo; Patrizia Licata; Alessio Filippo Peritore; Rosalia Crupi; Annamaria Passantino
Journal:  Antibiotics (Basel)       Date:  2021-05-28
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.